BELLEVUE, Wash., April 7, 2008 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the appointment of David P. Holveck to its Board of Directors. The appointment increases Board membership to eight.
Holveck, 62, is the President, Chief Executive Officer and a Director of Endo Pharmaceuticals. He is the former President of Johnson & Johnson Development Corp. and a Vice President of Corporate Development with Johnson & Johnson (NYSE: JNJ). Previously, he was President and Chief Executive Officer of Centocor Inc. until its acquisition by Johnson & Johnson in 1999. Prior to joining Centocor, he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.
"I am pleased and excited to welcome Dave Holveck to our Board," said Llew Keltner, LSO's President and Chief Executive Officer. "He will be a tremendous asset to our company, especially at such an important time in the company's evolution as we reach key milestones in the late-stage development of our light-activated drug therapy."
"Joining the LSO board is a great opportunity to help guide this dynamic company in its future growth and accomplishment," added Holveck. "Together with the other board members, I hope to ensure that the company's potentially revolutionary therapy finds the best possible pathway into medical practice."
Holveck is a member of the Board of Trustees for The Fund for West Chester University, the Board of Directors of the Eastern Technology Council and Cleveland Clinic's Industrial Advisory Board. He has served as a board member of the Pharmaceutical Research and Manufacturing Association (PhRMA) and the Biotechnology Industry Organization (BIO).
He received a Bachelor of Science degree in education/science from West Chester University.
ABOUT LIGHT SCIENCES ONCOLOGY
Light Sciences Oncology, Inc. (LSO) is developing Light Infusion
Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment for
solid tumors, to provide safer and more effective treatment to cancer
patients. In addition to the Phase III trials underway in hepatocellular
carcinoma and colorectal cancer metastatic to the liver, the Company has
completed a Phase II clinical trial of Litx in glioma. LSO has widened the
scope of potential therapeutic applications for Litx to include benign
neoplasms such as benign prostatic hyperplasia (BPH) and uterine fibroids,
as well as vascular disease, dermatology, and all other applications of the
versatile Litx platform. The Company has positioned itself for growth with
a strong portfolio of intellectual property, innovative applications in
development, and an exceptionally talented team.
Robert M. Littauer
Vice President, Chief Financial Officer and Treasurer
Llew Keltner, M.D., Ph.D.
President and CEO
Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light Sciences Oncology, Inc.
|SOURCE Light Sciences Oncology, Inc.|
Copyright©2008 PR Newswire.
All rights reserved